Selling instruments and reagents as one set — a company that sells counting results (1985)

Selling the result, not the machine

The core of this decision lies in what the company defined itself as selling. A maker of blood cell counters would naturally head toward building and selling a faster, more accurate machine. Toa Medical Electronics instead defined itself as a company selling the “counting result” that the machine produces, rather than the machine itself. This pattern — the instrument as the entrance, the reagent as the consumable that earns continuously — can be read as a choice to place the weight of the business one step back from the performance race over the device alone.

A mechanism for charging continuously through consumables is widely known today under the name subscription. But it is no small thing that in blood testing — a field where instrument and dedicated reagent are inseparable — a mid-sized company only recently founded pursued this pattern so thoroughly, so early. Rather than chasing volume on one-off sales, earning from a relationship that keeps being used: the origin of the profit structure that keeps Sysmex chosen around the world lies in that unglamorous choice of business design.